5 Best Life Sciences Stocks To Buy Right Now

5 Best Life Sciences Stocks To Buy Right Now: Minerva Neurosciences Inc (NERV)

Minerva Neurosciences, Inc. is a biopharmaceutical company focused on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system (CNS), diseases. The Companys product candidates are MIN-101, a compound it is developing for the treatment of patients with schizophrenia, and MIN-117, a compound it is developing for the treatment of patients suffering from depressive disorder (MDD). In addition, the Companys portfolio includes MIN-202, a compound it is co-developing for the treatment of patients suffering from primary and secondary insomnia, and MIN-301, a compound it is developing for the treatment of patients suffering from Parkinson's disease. Its product candidates include MIN-101, MIN-117, MIN-202 and MIN-301.

MIN-101 is a molecule behaving as an antagonist of 5-HT2A and sigma2 receptors, which the Company is developing for the treatment of patients with schizophrenia. MIN-117 is a molecule behaving mainly as an antagonist on 5-HT1A receptors and as an inhibitor of both serotonin and dopamine reuptake, which it is developing for the treatment of patients with MDD. MDD is a subtype and a severe form of depression, with 6% of MDD patients committing suicide. In addition, an available therapy has several side effects, including cognitive impairment, sexual dysfunction and sleep disorders that lead many patients to discontinue therapy. MIN-301 is a soluble recombinant form of the Neuregulin-1b1 (NRG-1b1), protein, which it is developing for the treatment of patients with Parkinson's disease

MIN-202 is a molecule acting as a selective orexin 2 receptor antagonists, which the Company is co-developing for the treatment of patients with insomnia. Insomnia can be the primary condition for patients or a secondary symptom of another medical or psychiatric condition, such as MDD or schizophrenia. It intends to evaluate MIN-202! as a treatment in primar y insomnia, as well as secondary insomnia as an adjunctive therapy with an antidepressant for the treatment of mood disorders. Unlike many therapies that activate sleep-promoting neurotransmitters, MIN-202 is specifically targeted towards inhibiting the activity of the neurons that promote wakefulness. The Company is co-developing MIN-202 with Janssen Pharmaceutica N.V.

Advisors' Opinion:

• [By Monica Gerson]

  Minerva Neurosciences, Inc.(NASDAQ: NERV) shares rose 58.33% to $9.50 in pre-market trading following positive study results.

  Frontline Ltd. (NYSE: FRO) shares jumped 14.84% to $2.94 in pre-market trading following positive comments from Karen Finerman on CNBC.

source from Top Penny Stocks For 2015:http://www.seekpennystocks.com/5-best-life-sciences-stocks-to-buy-right-now-2.html